Highlights

• Echo IQ shares gained AU$0.055 (10.679%) to AU$0.570 today, the same day it released an FDA update on 17 September 2026
• The company says the FDA's concerns relate only to statistical analysis, not the core technology of EchoSolv HF
• An administrative appeal, an FDA Ombudsman review and a new 510(k) submission are all being assessed

Shares Rebound on Announcement Day

Echo IQ Limited (ASX EIQ) shares were among the stronger performers on the market today, rising AU$0.055, or 10.679%, to last trade at AU$0.570. The move came on the same day the Sydney-based AI and medical technology company gave investors a detailed update on its efforts to secure US regulatory clearance for EchoSolv HF, its software designed to support the detection of heart failure.

Background to the FDA Decision

On 8 September 2026, Echo IQ disclosed that the US Food and Drug Administration (FDA) had issued a Not Substantially Equivalent (NSE) determination on its first 510(k) application for EchoSolv HF. The 510(k) process requires a company to show that its device is substantially equivalent to a product already legally marketed in the US. An NSE outcome means the regulator was not satisfied on that point, so the device cannot be sold in the US under that submission.

Company Says Issues Are Limited in Scope

In its announcement dated 17 September 2026, Echo IQ said it has completed an initial review of the FDA's feedback and documentation. According to the company, the matters raised are confined to parts of the statistical analysis used to support the product's clinical validation. Its assessment did not find any concerns about the underlying technology or the core functionality of EchoSolv HF. On that basis, the company believes there is a clear path forward and that clearance could potentially be achieved over the coming quarters. Work has already started with regulatory consultants and legal counsel, and Echo IQ said it remains committed to working closely with the FDA to resolve every issue cited.

Three Pathways Under Review

Echo IQ has identified three possible routes. The first is an administrative appeal, which would allow the company to challenge the FDA's scientific and regulatory conclusions and gain a better understanding of the agency's reasoning. The timeline is not fixed and, in some cases, could be shorter than 90 days. An appeal could lead to the determination being overturned, the FDA reopening its review and potentially clearing the product, or a request to resubmit with clearer guidance on what must be addressed. The second route is seeking assistance from the FDA Ombudsman, who can help arrange a procedural review of the decision and support engagement with the FDA review team. The third is lodging a new 510(k) submission, a process the company says can be completed over the coming quarters.

Commercial Partnerships Remain in Place

Importantly, Echo IQ confirmed there has been no material impact on its strategic partner agreements, including those with Advara HeartCare, Mayo Clinic and Pro Medicus Limited. However, a further AU$10 million investment tranche under the company's convertible note arrangement with Pro Medicus is conditional on FDA clearance of EchoSolv HF, making the regulatory outcome significant for its funding plans.

Outlook

Echo IQ is not new to the US approval process. Its flagship product, EchoSolv AS, is already FDA-cleared as a clinical decision support aid for detecting severe aortic stenosis, and the company runs US operations from Greenville, Delaware. That experience may help as it works through the EchoSolv HF process. However, Echo IQ cautions that FDA clearance remains subject to regulatory review and may not be secured within the expected timeframe or ultimately granted. The next key steps for investors to watch are Echo IQ's choice of regulatory pathway, the FDA's response, and whether the conditional Pro Medicus funding is ultimately unlocked.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au